China’s National Drug Administration has granted rapid approval for Roche’s lung cancer treatment Alecensa (alectinib).
Chinese regulators have in the past approved drugs years later than other regions such as Europe and the United States. However the lengthy regulatory process and the associated lack of access to drugs has turned patients towards the grey market.
Original Article: Chinese regulators approve Roche's Alecensa in regulatory shift